CAR T cell therapy in type 1 diabetes: what we know and what remains to be explored

Sandesh Kumar Pattanaik, Diptirani Rath, Amir Mansour Moeini, Mohsen Nabi Afjadi · 2025

Read CAR T cell therapy in type 1 diabetes: what we know and what remains to be explored by Sandesh Kumar Pattanaik, Diptirani Rath, Amir Mansour Moeini, Mohsen Nabi Afjadi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12661798.txt.

Description

Sandesh Pattanaik, Diptirani Rath, Amir Moeini, and Mohsen Nabi Afjadi published a review in twenty twenty-five on importing cancer's star therapy, engineered CAR T cells, into type 1 diabetes. There the enemy is not a tumor but the immune system's own attack on insulin-producing beta cells, which no current therapy reverses.

The review assembles what is known about retraining T cells to protect, rather than destroy, the pancreatic targets, including regulatory cell variants. Achievements in blood cancers prove the engineering works; diabetes poses different problems of target choice, safety, and durability. The authors catalogue the obstacles honestly and sketch personalized designs as the path forward. A paradigm shift is proposed, not proclaimed, with the unexplored territory clearly marked.

Catalog record

CREATORSandesh Kumar Pattanaik, Diptirani Rath, Amir Mansour Moeini, Mohsen Nabi Afjadi
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE68 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12661798

Browse the full library · About the Tower of Babel